Bing de ling®, a Chinese herbal formula, inhibits cancer cells growth via p53

Frontiers in Bioscience - Elite

Volumn 2 E, Issue 1, 2010, Pages 221-230

  Zhang, Yingtao ^a   Dong, Huiqin ^a   Li, Zhenyu ^b   Xiang, Shengyan ^a   Zhu, Yuyan ^a   Zhang, Mu ^a   Liu, Jing ^d   Bai, Wenlong ^a,b   Nicosia, Santo V ^a,c   Chen, Jiandong ^b   Zhao, Ruan Jin ^a   Zhang, Xiaohong ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b Programs of Molecular Oncology   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d Center for Traditional Chinese Medicine   (United States)

Author keywords

Cell cycle; MDMX; Ovarian cancer; P53

Indexed keywords

ANTINEOPLASTIC AGENT; HERBACEOUS AGENT; LUCIFERASE; MDM4 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN P53; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ARTICLE; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HUMAN; IMMUNOBLOTTING; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUGS, CHINESE HERBAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; LUCIFERASES; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; TETRAZOLIUM SALTS; THIAZOLES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77954512708     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: 10.2741/e84     Document Type: Article

References (29)

1. Lee, R. T., F. J. Hlubocky, J. J. Hu, R. S. Stafford & C. K. Daugherty: An international pilot study of oncology physicians' opinions and practices on Complementary and Alternative Medicine (CAM). Integr Cancer Ther, 7, 70-5 (2008) (Pubitemid 351806534)
2. Niu, G., J. Tan, J. G. Turner, J. G. Brabham, L. G. Burdelya, B. E. Crucian, H. Wall-Apelt, R. J. Zhao & H. Yu: Bing de ling, a Chinese herbal formula, stimulates multifaceted immunologic responses in mice. DNA Cell Biol, 19, 515-20 (2000) (Pubitemid 32186446)
3. Xu, Q., J. G. Brabham, S. Zhang, P. Munster, K. Fields, R. J. Zhao & H. Yu: Chinese herbal formula, Bing De Ling, enhances antitumor effects and ameliorates weight loss induced by 5-fluorouracil in the mouse CT26 tumor model. DNA Cell Biol, 24, 470-5 (2005) (Pubitemid 40994559)
4. Shoemaker, M., B. Hamilton, S. H. Dairkee, I. Cohen & M. J. Campbell: In vitro anticancer activity of twelve Chinese medicinal herbs. Phytother Res, 19, 649-51 (2005) (Pubitemid 41375251)
5. Su, Y. T., H. L. Chang, S. K. Shyue & S. L. Hsu: Emodin induces apoptosis in human lung adenocarcinoma cells through a reactive oxygen species-dependent mitochondrial signaling pathway. Biochem Pharmacol, 70, 229-41 (2005)
6. Huang, Q., H. M. Shen & C. N. Ong: Emodin inhibits tumor cell migration through suppression of the phosphatidylinositol 3-kinase-Cdc42/Rac1 pathway. Cell Mol Life Sci, 62, 1167-75 (2005) (Pubitemid 40868533)
7. Zhang, L. & M. C. Hung: Sensitization of HER-2/neuoverexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. Oncogene, 12, 571-6 (1996) (Pubitemid 26059652)
8. Zhang, L., Y. K. Lau, L. Xi, R. L. Hong, D. S. Kim, C. F. Chen, G. N. Hortobagyi, C. Chang & M. C. Hung: Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-Associated properties. Oncogene, 16, 2855-63 (1998) (Pubitemid 28383270)
9. Peng, Y., C. Li, L. Chen, S. Sebti & J. Chen: Rescue of mutant p53 transcription function by ellipticine. Oncogene, 22, 4478-87 (2003) (Pubitemid 36920691)
10. Hu, B., D. M. Gilkes & J. Chen: Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. Cancer Res, 67, 8810-7 (2007) (Pubitemid 47437457)
11. Naidu, K. A., Q. Fang, K. A. Naidu, J. Q. Cheng, S. V. Nicosia & D. Coppola: P53 enhances ascorbyl stearateinduced G2/M arrest of human ovarian cancer cells. Anticancer Res, 27, 3927-34 (2007)
12. Bagnoli, M., E. Balladore, E. Luison, P. Alberti, F. Raspagliesi, B. Marcomini, S. Canevari & D. Mezzanzanica: Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment. Mol Cancer Ther, 6, 762-72 (2007) (Pubitemid 46332477)
13. Wang, Y. A., S. K. Johnson, B. L. Brown, L. M. McCarragher, K. Al-Sakkaf, J. A. Royds & P. R. Dobson: Enhanced anti-cancer effect of a phosphatidylinositol-3 kinase inhibitor and doxorubicin on human breast epithelial cell lines with different p53 and oestrogen receptor status. Int J Cancer, 123, 1536-44 (2008)
14. Markman, M.: Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies. Trends Pharmacol Sci (2008)
15. Ye, F., S. Jiang, H. Volshonok, J. Wu & D. Y. Zhang: Molecular mechanism of anti-prostate cancer activity of Scutellaria baicalensis extract. Nutr Cancer, 57, 100-10 (2007) (Pubitemid 46871574)
16. Bringold, F. & M. Serrano: Tumor suppressors and oncogenes in cellular senescence. Exp Gerontol, 35, 317-29 (2000) (Pubitemid 30314689)
17. Wang, X. W., Q. Zhan, J. D. Coursen, M. A. Khan, H. U. Kontny, L. Yu, M. C. Hollander, P. M. O'Connor, A. J. Fornace, Jr. & C. C. Harris: GADD45 induction of a G2/M cell cycle checkpoint. Proc Natl Acad Sci U S A, 96, 3706-11 (1999) (Pubitemid 29168974)
18. el-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler & B. Vogelstein: WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-25 (1993) (Pubitemid 23346378)
19. Huang, Q., G. Lu, H. M. Shen, M. C. Chung & C. N. Ong: Anti-cancer properties of anthraquinones from rhubarb. Med Res Rev, 27, 609-30 (2007) (Pubitemid 47282446)
20. Marine, J. C. & A. G. Jochemsen: Mdmx and Mdm2: brothers in arms? Cell Cycle, 3, 900-4 (2004) (Pubitemid 40179469)
21. Shvarts, A., W. T. Steegenga, N. Riteco, T. van Laar, P. Dekker, M. Bazuine, R. C. van Ham, W. van der Houven van Oordt, G. Hateboer, A. J. van der Eb & A. G. Jochemsen: MDMX: a novel p53-binding protein with some functional properties of MDM2. Embo J, 15, 5349-57 (1996) (Pubitemid 26336217)
22. Little, N. A. & A. G. Jochemsen: Hdmx and Mdm2 can repress transcription activation by p53 but not by p63. Oncogene, 20, 4576-80 (2001) (Pubitemid 32772440)
23. Pan, Y. & J. Chen: MDM2 promotes ubiquitination and degradation of MDMX. Mol Cell Biol, 23, 5113-21 (2003) (Pubitemid 36950868)
24. Kawai, H., D. Wiederschain, H. Kitao, J. Stuart, K. K. Tsai & Z. M. Yuan: DNA damage-induced MDMX degradation is mediated by MDM2. J Biol Chem, 278, 45946-53 (2003) (Pubitemid 37432741)
25. Honda, R., H. Tanaka & H. Yasuda: Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett, 420, 25-7 (1997) (Pubitemid 28037193)
26. Haupt, Y., R. Maya, A. Kazaz & M. Oren: Mdm2 promotes the rapid degradation of p53. Nature, 387, 296-9 (1997) (Pubitemid 27220766)
27. Kubbutat, M. H., S. N. Jones & K. H. Vousden: Regulation of p53 stability by Mdm2. Nature, 387, 299-303 (1997) (Pubitemid 27220767)
28. Roth, J., M. Dobbelstein, D. A. Freedman, T. Shenk & A. J. Levine: Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. Embo J, 17, 554-64 (1998) (Pubitemid 28045495)
29. Vassilev, L. T.: Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle, 3, 419-21 (2004) (Pubitemid 40278226)